Le Lézard
Classified in: Health
Subject: SVY

Global Market Study on Cushing's Syndrome and Acromegaly Treatment: Rising Demand for Non Invasive Treatment Trending the Global Market


LONDON, Nov. 13, 2018 /PRNewswire/ -- This report offers an eight year forecast on the global Cushing's syndrome and Acromegaly Treatment market. The primary objective of the report is to offer updates and information related to the opportunities in the Cushing's syndrome and Acromegaly Treatment market.



Download the full report: https://www.reportbuyer.com/product/5609135



Report Description
In terms of revenue, the global Cushing's syndrome and Acromegaly treatment market is expected to register a CAGR of 9.3% during the forecast period, 2018?2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global Cushing's syndrome and Acromegaly treatment market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global Cushing's syndrome and Acromegaly treatment market are presented in the report.

The global market for Cushing's syndrome and Acromegaly treatment is expected to witness higher single digit growth value owing to the growing prevalence and rates of screening of Cushing's syndrome and acromegaly, growth in awareness and development of healthcare infrastructure.The increase in incidence of Cushing's syndrome and Acromegaly is the major factor driving the growth of the global Cushing's syndrome and Acromegaly treatment market.

The advances in imaging such as advent of magnetic resonance imaging, computed tomography and among others are increasing the adoption of Cushing's syndrome and Acromegaly treatment. The demand for non-invasive treatment coupled with the relapse rates of Cushing's syndrome and Acromegaly after surgery is driving a large adoption of drug treatment for Cushing's syndrome and Acromegaly Treatment market.

Increasing investments in the research and development coupled with the entry of deep pocketed companies in the Cushing's syndrome and Acromegaly treatment market is expected to generate momentum and growth opportunities for the Cushing's syndrome and Acromegaly Treatment market.The manufacturers are focusing on the production of targeted therapies and technologically advanced products.

Technological advancements is resulting in faster product development and shorter lifecycles of the products.

The report does not includes the revenue generated by the sale of Cushing's syndrome and Acromegaly products used in fields other than treatment. Currency fluctuations and inflation are not considered while calculating the revenue of the Cushing's syndrome and Acromegaly treatment market.

Revenue from the Cushing's syndrome and Acromegaly treatment market in countries of Asia Pacific such as China is expected to expand at the relatively higher CAGR due to lower install base, which reflects high market equity and developing healthcare infrastructure.To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the product type, indications, end users and regions.

The report provides analysis of the global Cushing's syndrome and Acromegaly treatment market in terms of market value (US$ Mn).

By drug type, the global Cushing's syndrome and Acromegaly treatment market is segmented into Cushing's syndrome treatment and Acromegaly treatment.The Cushing's syndrome treatment is further sub segmented into Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, and other Off-label.

The Acromegaly treatment is further sub segmented into Somatostatin, Glucocorticoid Receptor Inhibitors, and other Off-label. Based on the distribution channels, the global Cushing's syndrome and Acromegaly treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The report begins with the market definition of Cushing's syndrome and Acromegaly treatment, followed by definitions of the different segment types. The market dynamics section includes an analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global Cushing's syndrome and Acromegaly treatment market.

The report analyses the Cushing's syndrome and Acromegaly treatment market on the basis of the drug types and distribution channels and presents forecast in terms of value for the next 10 years. On the basis of drug types, the global Cushing's syndrome and Acromegaly treatment market is segmented into:

Cushing's Syndrome Treatment
Glucocorticoid Receptor Inhibitors
Somatostatin
Ketoconazole HRA
Other Off-label

Acromegaly Treatment
Somatostatin
Glucocorticoid Receptor Inhibitors
Other Off-label

On the basis of the distribution channels, the global Cushing's syndrome and Acromegaly treatment market is segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of region, the global Cushing's syndrome and Acromegaly treatment market is segmented into:

North America
U.S.
Canada
Western Europe
Germany
France
U.K.
Russia
Spain
Rest of Western Europe
Latin America
Brazil
Mexico
Rest of Latin America
Asia Pacific
Australia
China
Japan
India
Rest of Asia Pacific
Rest of World
GCC Countries
South Africa
Rest of World

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global Cushing's syndrome and Acromegaly treatment market.

Another key feature of this report is the analysis of the key segments in terms of absolute dollar opportunity.This is usually overlooked while forecasting the market.

However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the Cushing's syndrome and Acromegaly treatment market.To understand the key segments in terms of their growth and performance in the global Cushing's syndrome and Acromegaly treatment market, Persistence Market Research has developed a market attractiveness index.

The resulting index will help identify the existing market opportunities in Cushing's syndrome and Acromegaly treatment market.

In the final section of the report, a 'competitive landscape' has been included to provide a dashboard view of the key companies operating in the global Cushing's syndrome and Acromegaly treatment market.This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the Cushing's syndrome and Acromegaly treatment market.

However, this section also includes market strategies and SWOT analysis of the key players operating in the global Cushing's syndrome and Acromegaly treatment market.

Detailed profiles of the manufacturers of Cushing's syndrome and Acromegaly Treatment are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the Cushing's syndrome and Acromegaly treatment market are Novartis AG, Corcept Therapeutics, HRA Pharma, Bristol-Myers Squibb Company, Pfizer Inc., Ipsen Biopharmaceuticals, Inc. among others.

Download the full report: https://www.reportbuyer.com/product/5609135

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: